COVID-19: Video shows chief UK medical officer being harassed taipeitimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from taipeitimes.com Daily Mail and Mail on Sunday newspapers.
Public Health England
Vaccines highly effective against B.1.617.2 variant after 2 doses
New study by PHE shows for the first time that 2 doses of the COVID-19 vaccines are highly effective against the B.1.617.2 variant first identified in India.
Vaccine effectiveness against symptomatic disease from the B.1.617.2 variant is similar after 2 doses compared to the B.1.1.7 (Kent) variant dominant in the UK, and we expect to see even higher levels of effectiveness against hospitalisation and death.
The study found that, for the period from 5 April to 16 May:
the Pfizer-BioNTech vaccine was 88% effective against symptomatic disease from the B.1.617.2 variant 2 weeks after the second dose, compared to 93% effectiveness against the B.1.1.7 variant
New study by PHE shows for the first time that 2 doses of the COVID-19 vaccines are highly effective against the B.1.617.2 variant first identified in India.
Southampton is taking part in a world-first trial. SOUTHAMPTON is spearheading a world-first trial to identify the most effective booster vaccines in the battle against Covid-19. A new government-funded initiative will determine the immune responses triggered by each of the seven vaccines developed in a bid to defeat the killer virus. The trial will be led by University Hospital Southampton NHS Foundation Trust. A trust spokesperson said: Volunteers from Southampton, Portsmouth and Bournemouth will soon be able to receive a third ‘booster’ vaccine through a new clinical trial launching this week. The study, backed by £19.3m of government funding through the Vaccines Taskforce, will be run at University Hospital Southampton, University Hospitals Dorset and the Portsmouth Research Hub (Portsmouth Hospitals).